次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

アレルギー性鼻炎治療薬の世界市場2014-2024年

Allergic Rhinitis Drugs Market Forecast 2014-2024: Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2014年8月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文274ページになります。
商品コード:VGN267

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
当レポートでは、アレルギー性鼻炎治療薬の世界市場は2014年に113億ドルに達し、2024年にかけて拡大すると予測しています。同治療薬への需要増大、医療保険適用の拡大、世界経済の回復、同治療における免疫療法セグメントの成長などは市場の促進要因となるでしょう。地域的には特に、インド、中国、メキシコ、ブラジルで高成長の継続が見込まれます。当レポートでは2024年に至る市場予測、詳細なセグメント別予測分析に加え、市場動向、研究開発動向、リーディング企業情報などを概略以下の構成でお届けいたします。

【レポート構成概要】
・アレルギー性鼻炎治療薬の世界市場予測2014-2024年
・全274ページ、204個のデータ表、グラフ類で分析定量化
・市場成長率、市場シェア情報
・専門家オピニオンインタビュー:
• Maureen Jenkins, Director of Clinical Services, Allergy UK
• Tonya Winders, President & CEO, Allergy and Asthma Network Mothers of Asthmatics (AANMA)
• Jonathan Bernstein, Professor, University of Cincinnati College of Medicine
• Hazel Econs, Financial & Marketing Director, Allergy Medical UK
• Kimihiro Okubo, Chairman and Professor, Nippon Medical School

・セグメント別市場予測2014-2024年VGN267_Allergic Rhinitis Drugs Market Forecast 2014-2024 Cover.jpgレポート表紙
• 経口抗ヒスタミン薬Oral antihistamines
• 点鼻コルチコステロイドIntranasal corticosteroids
• 点鼻抗ヒスタミン薬Intranasal antihistamines
• 免疫療法Immunotherapy
• その他薬剤Other drugs.
(※全セグメント売上ベースのデータ記載。点鼻コルチコステロイドと点鼻抗ヒスタミン薬は各出荷数量、および主要製品売上、出荷数データも追加掲載。詳細は目次参照)

・主要26製品、製品別売上予測2014-2024年
(※以下ブランドを含む26製品掲載)
• Nasonex
• Allegra/Allegra-D/Allegra OTC
• Zyrtec/Zyrtec D
• Claritin/Claritin OTC
• Astepro
• Avamys/Veramyst
• Xyzal
• Allelock
• Staloral
• Clarinex

・主要12ヶ国、国別市場予測2014-2024年
• 米国
• 日本
• 中国
• ドイツ
• フランス
• 英国
• イタリア
• スペイン
• インド
• ブラジル
• ロシア
• メキシコ
• その他地域Rest of the World

・リーディング企業8社プロフィール。アレルギー性鼻炎薬関連売上、業績、新製品、提携、将来展望
• ALK-Abelló
• GSK
• Johnson & Johnson (J&J)
• Kyowa Hakko Kirin
• Merck & Co. (Merck)
• Sanofi
• Stallergenes
• UCB.

・研究開発動向、新製品パイプライン
• 経口抗ヒスタミン薬Oral antihistamines
• 点鼻コルチコステロイド
• 免疫療法
• 皮下免疫療法
• 舌下免疫療法錠剤
• Toll様受容体拮抗薬、新たな小分子
• その他の進捗

・市場動向諸論点
• 有病率の増加に伴う治療薬需要の増大
• 免疫療法分野の力強い研究開発パイプライン
• 特許期限切れ、ジェネリックとの競合
• 免疫療法や併用薬などの成長分野
• 処方薬からOTC薬への転換
• 価格設定と費用回収

visiongain is a trading partner with the US Federal Government
【レポート詳細目次は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Allergic Rhinitis Drugs Market Forecast 2014-2024: Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines

Table of Contents

1. Report Overview

1. Report Overview
1.1 Global Allergic Rhinitis Drugs Market Overview
1.2 Global Allergic Rhinitis Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Allergic Rhinitis

2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 A Brief Overview of Allergy
2.3 Allergic Rhinitis
2.3.1 The Global Prevalence of Allergic Rhinitis
2.3.2 Pathophysiology of Allergic Rhinitis: IgEs and Mast Cells
2.3.3 Symptoms of Allergic Rhinitis
2.3.4 Classification of Allergic Rhinitis
2.3.4.1 Non-Allergic Rhinitis and Mixed Rhinitis
2.3.5 Seasonal Allergic Rhinitis (Hay Fever)
2.3.6 Perennial Allergic Rhinitis
2.3.7 Diagnosis of Allergic Rhinitis
2.4 Treatment of Allergic Rhinitis
2.4.1 Antihistamines
2.4.1.1 First-Generation Antihistamines
2.4.1.2 Second- and Third-Generation Antihistamines
2.4.2 Corticosteroids
2.4.2.1 First-, Second- and Third-Generation Intranasal Corticosteroids
2.4.2.2 Combination Drug Products
2.4.3 Leukotriene Receptor Antagonists
2.4.4 Cromolyn (cromoglicic acid)
2.4.5 Decongestants
2.4.6 Saline Nasal Sprays
2.4.7 Immunotherapy and Vaccines
2.5 Phases of Clinical Trials
2.6 Scope of this Report
2.7 Currency Exchange Rates in This Report

3. Allergic Rhinitis Drugs: World Market 2014-2024

3.1 The World Allergic Rhinitis Drugs Market in 2013
3.1.1 Leading Allergic Rhinitis Drugs
3.1.2 Leading Companies in the Allergic Rhinitis Drugs Market
3.2 World Allergic Rhinitis Drugs Market: Sales Forecast 2014-2024
3.3 Oral Antihistamines Lead the World Allergic Rhinitis Drugs Market
3.4 How Will Segmental Market Shares Change to 2024?
3.5 World Allergic Rhinitis Drugs Market: Drivers and Restraints 2014-2024

4. Leading National Allergic Rhinitis Drugs Markets 2014-2024

4.1 Geographical Breakdown of the World Allergic Rhinitis Drugs Market
4.2 World Allergic Rhinitis Drugs Market: National Markets Forecast 2014-2024
4.2.1 How Will National Market Shares Change to 2024?
4.3 The US Allergic Rhinitis Drugs Market 2014-2024
4.3.1 US Allergic Rhinitis Drugs Market Forecast 2014-2024
4.3.2 US Allergic Rhinitis Drugs Market: Trends and Developments
4.3.2.1 Rx-to-OTC Switching of Intranasal Corticosteroids
4.3.2.2 Affordable Care Act: Expanding Medicare Coverage
4.4 Chinese Allergic Rhinitis Drugs Market 2014-2024
4.4.1 Chinese Allergic Rhinitis Drugs Market Forecast 2014-2024
4.4.2 Chinese Allergic Rhinitis Drugs Market: Trends and Developments
4.4.2.1 Air Pollution Associated With Increasing Prevalence
4.4.2.2 Expansion of Healthcare Coverage and Reimbursement
4.5 Japanese Allergic Rhinitis Drugs Market 2014-2024
4.5.1 Japanese Allergic Rhinitis Drugs Market Forecast 2014-2024
4.5.2 Japanese Allergic Rhinitis Drugs Market: Trends and Developments
4.5.2.1 Cedar Reforestation and the Hay Fever Epidemic
4.5.2.2 Generic Penetration to Reach 60% by 2018?
4.5.2.3 Genetically Modified Rice as Immunotherapy
4.6 EU5 Allergic Rhinitis Drugs Market 2014-2024
4.6.1 German Allergic Rhinitis Drugs Market Forecast 2014-2024
4.6.2 French Allergic Rhinitis Drugs Market Forecast 2014-2024
4.6.3 UK Allergic Rhinitis Drugs Market Forecast 2014-2024
4.6.4 Italian Allergic Rhinitis Drugs Market Forecast 2014-2024
4.6.5 Spanish Allergic Rhinitis Drugs Market Forecast 2014-2024
4.6.6 EU5 Allergic Rhinitis Drugs Market: Trends and Developments
4.6.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.6.6.2 France: Social Security Finance Bill 2014
4.6.6.3 UK: Increasing Burden of Allergy
4.6.6.4 Italy: Austerity Measures Limiting Growth
4.6.6.5 Spain: The Start of Recovery in the Spanish Economy
4.7 Russian Allergic Rhinitis Drugs Market 2014-2024
4.7.1 Russian Allergic Rhinitis Drugs Market Forecast 2014-2024
4.7.2 Russian Allergic Rhinitis Drugs Market: Trends and Developments
4.7.2.1 Pharma2020 and the Russian Pharmaceutical Industry
4.8 Indian Allergic Rhinitis Drugs Market 2014-2024
4.8.1 Indian Allergic Rhinitis Drugs Market Forecast 2014-2024
4.8.2 Indian Allergic Rhinitis Drugs Market: Trends and Developments
4.8.2.1 Drug Prices Control Order 2013
4.8.2.2 Expansion of Healthcare Provision
4.9 Brazilian Allergic Rhinitis Drugs Market 2014-2024
4.9.1 Brazilian Allergic Rhinitis Drugs Market Forecast 2014-2024
4.9.2 Brazilian Allergic Rhinitis Drugs Market: Trends and Developments
4.9.2.1 Increasing Access to Medicines
4.10 Mexican Allergic Rhinitis Drugs Market 2014-2024
4.10.1 Mexican Allergic Rhinitis Drugs Market Forecast 2014-2024
4.10.2 Mexican Allergic Rhinitis Drugs Market: Trends and Developments
4.10.2.1 Seguro Popular: Mexican Healthcare Reform

5. Oral Antihistamines Market 2014-2024

5.1 Oral Antihistamines: A Market in Decline
5.2 Leading Oral Antihistamines in 2013
5.3 Oral Antihistamines: Market Forecast 2014-2024
5.4 Market Share of Leading Oral Antihistamines to 2024
5.5 Oral Antihistamines: Trends and Developments
5.5.1 Patent Expiry and Generic Competition
5.5.2 The Rx-to-OTC Rush
5.5.3 Combination Therapy with Intranasal Corticosteroids
5.6 Allegra/Allegra-D/Allegra OTC (fexofenadine, Sanofi)
5.6.1 Allegra/Allegra OTC: Sales Forecast 2014-2024
5.7 Zyrtec/Zyrtec D (cetirizine, Johnson & Johnson/UCB/GSK)
5.7.1 Zyrtec/Zyrtec D: Sales Forecast 2014-2024
5.8 Claritin/Claritin OTC (loratadine, Merck & Co.)
5.8.1 Claritin/Claritin OTC: Sales Forecast 2014-2024
5.9 Xyzal (levocetirizine, Sanofi/UCB/GSK)
5.9.1 Xyzal: Sales Forecast 2014-2024
5.10 Allelock (olopatadine, Kyowa Hakko Kirin)
5.10.1 Allelock: Sales Forecast 2014-2024
5.11 Clarinex (desloratadine, Merck & Co.)
5.11.1 Clarinex: Sales Forecast 2014-2024
5.12 Talion (bepotastine, Mitsubishi Tanabe)
5.12.1 Talion: Sales Forecast 2014-2024
5.13 Ebastel (ebastine, Almirall/Takeda/Dainippon Sumitomo)
5.13.1 Ebastel: Sales Forecast 2014-2024
5.14 Other Oral Antihistamines

6. Intranasal Corticosteroids Market 2014-2024

6.1 Intranasal Corticosteroids: First-line for Allergic Rhinitis
6.2 Leading Intranasal Corticosteroids in 2013
6.3 Intranasal Corticosteroids: Market Forecast by Value, 2014-2024
6.4 Intranasal Corticosteroids: Market Forecast by Volume, 2014-2024
6.5 Market Share of Leading Intranasal Corticosteroids to 2024
6.6 Intranasal Corticosteroids: Trends and Developments
6.6.1 Nasonex Patent Expiry in 2014
6.6.2 Nasacort AQ Switched to OTC
6.7 Nasonex (mometasone, Merck)
6.7.1 Nasonex: Sales Forecast by Value, 2014-2024)
6.7.2 Nasonex: Sales Forecast by Volume, 2014-2024)
6.8 Avamys/Veramyst (fluticasone furoate, GSK)
6.8.1 Avamys/Veramyst: Sales Forecast by Value, 2014-2024)
6.8.2 Avamys/Veramyst: Sales Forecast by Volume, 2014-2024)
6.9 Flixonase/Flonase (fluticasone propionate, GSK)
6.9.1 Flixonase/Flonase: Sales Forecast by Value, 2014-2024)
6.9.2 Flixonase/Flonase: Sales Forecast by Volume, 2014-2024)
6.10 Rhinocort (budesonide, AstraZeneca)
6.10.1 Rhinocort: Sales Forecast by Value, 2014-2024)
6.10.2 Rhinocort: Sales Forecast by Volume, 2014-2024)
6.11 Omnaris (ciclesonide, Dainippon Sumitomo/Takeda)
6.11.1 Omnaris: Sales Forecast by Value, 2014-2024)
6.11.2 Omnaris: Sales Forecast by Volume, 2014-2024)
6.12 Beconase/Beconase AQ (beclometasone, GSK/Omega Pharma)
6.12.1 Beconase/Beconase AQ: Sales Forecast by Value, 2014-2024)
6.12.2 Beconase/Beconase AQ: Sales Forecast by Volume, 2014-2024)
6.13 Nasacort (triamcinolone, Sanofi)
6.13.1 Nasacort: Sales Forecast by Value, 2014-2024)
6.13.2 Nasacort: Sales Forecast by Volume, 2014-2024)
6.14 QNasl (beclometasone, Teva)
6.14.1 QNasl: Sales Forecast by Value, 2014-2024)
6.14.2 QNasl: Sales Forecast by Volume, 2014-2024)
6.15 Zetonna (ciclesonide, Dainippon Sumitomo)
6.15.1 Zetonna: Sales Forecast by Value, 2014-2024)
6.15.2 Zetonna: Sales Forecast by Volume, 2014-2024)
6.16 Generic Intranasal Corticosteroids
6.16.1 Generic Intranasal Beclometasone
6.16.1.1 Generic Intranasal Beclometasone: Sales Forecast by Value, 2014-2024
6.16.1.2 Generic Intranasal Beclometasone: Sales Forecast by Volume, 2014-2024
6.16.2 Generic Intranasal Budesonide
6.16.2.1 Generic Intranasal Budesonide: Sales Forecast by Value, 2014-2024
6.16.2.2 Generic Intranasal Budesonide: Sales Forecast by Volume, 2014-2024
6.16.3 Generic Intranasal Flunisolide
6.16.3.1 Generic Intranasal Flunisolide: Sales Forecast by Value, 2014-2024
6.16.3.2 Generic Intranasal Flunisolide: Sales Forecast by Volume, 2014-2024
6.16.4 Generic Intranasal Fluticasone
6.16.4.1 Generic Intranasal Fluticasone: Sales Forecast by Value, 2014-2024
6.16.4.2 Generic Intranasal Fluticasone: Sales Forecast by Volume, 2014-2024
6.16.5 Generic Intranasal Mometasone
6.16.5.1 Generic Intranasal Mometasone: Sales Forecast by Value, 2014-2024
6.16.5.2 Generic Intranasal Mometasone: Sales Forecast by Volume, 2014-2024
6.16.6 Generic Intranasal Triamcinolone
6.16.6.1 Generic Intranasal Triamcinolone: Sales Forecast by Value, 2014-2024
6.16.6.2 Generic Intranasal Triamcinolone: Sales Forecast by Volume, 2014-2024

7. Intranasal Antihistamines Market 2014-2024

7.1 Intranasal Antihistamines: A Niche Segment
7.2 Leading Intranasal Antihistamines in 2013
7.3 Intranasal Antihistamines: Market Forecast by Value, 2014-2024
7.4 Intranasal Antihistamines: Market Forecast by Volume, 2014-2024
7.5 Market Share of Leading Intranasal Antihistamines to 2024
7.6 Intranasal Antihistamines: Trends and Developments
7.6.1 Azelastine versus Olopatadine
7.6.2 Intranasal Combination Products
7.7 Astepro (azelastine, Meda)
7.7.1 Astepro: Sales Forecast 2014-2024
7.8 Patanase (olopatadine, Novartis)
7.8.1 Patanase: Sales Forecast 2014-2024
7.9 Astelin (azelastine, Meda)
7.9.1 Astelin: Sales Forecast 2014-2024
7.10 Dymista (azelastine/fluticasone, Meda)
7.10.1 Dymista: Sales Forecast 2014-2024
7.11 Generic Intranasal Azelastine
7.11.1 Generic Intranasal Azelastine: Sales Forecast by Value, 2014-2024
7.11.1 Generic Intranasal Azelastine: Sales Forecast by Volume, 2014-2024
7.12 Generic Intranasal Olopatadine
7.12.1 Generic Intranasal Azelastine: Sales Forecast by Value, 2014-2024
7.12.2 Generic Intranasal Azelastine: Sales Forecast by Volume, 2014-2024

8. Immunotherapy and Vaccines Market 2014-2024

8.1 Immunotherapy: Set for Rapid Expansion
8.2 Leading Immunotherapy Products in 2013
8.3 Immunotherapy: Market Forecast 2014-2024
8.4 Market Share of Leading Immunotherapy Products to 2024
8.5 Immunotherapy: Leading Companies
8.6 Immunotherapy: Trends and Developments
8.6.1 Subcutaneous and Sublingual Immunotherapy
8.6.2 Expansion into the US Market
8.6.3 Standardisation of Immunotherapy Products
8.6.4 Immunotherapy as a Preventative Treatment
8.7 Staloral (Grass pollen allergen extract, Stallergenes)
8.7.1 Staloral: Sales Forecast 2014-2024
8.8 Alutard SQ (Grass pollen allergen extract, ALK-Abelló)
8.8.1 Alutard SQ: Sales Forecast 2014-2024
8.9 Grazax/Grastek (Timothy grass pollen allergen extract, ALK-Abelló/Merck)
8.9.1 Grazax/Grastek: Sales Forecast 2014-2024
8.10 Oralair (Grass pollen allergen extract, Stallergenes/Greer)
8.10.1 Oralair: Sales Forecast 2014-2024
8.11 Ragwitek (Short ragweed pollen allergen extract, Merck)
8.11.1 Ragwitek: Sales Forecast 2014-2024

9. Leading Companies in the Allergic Rhinitis Drugs Market in 2014

9.1 Allergic Rhinitis Drugs: Merck & Co. Leads in a Fragmented Market
9.2 ALK-Abelló
9.2.1 ALK-Abelló: Allergic Rhinitis Drugs
9.2.2 ALK-Abelló: Allergic Rhinitis Sales Forecast 2014-2024
9.2.3 ALK-Abelló: Products in Development
9.2.4 ALK-Abelló: Recent Developments
9.2.4.1 ALK Collaborates with EddingPharm to Boost China Sales
9.2.4.2 Jext Product Recall
9.3 GSK
9.3.1 GSK: Allergic Rhinitis Drugs
9.3.2 GSK: Allergic Rhinitis Sales Forecast 2014-2024
9.3.3 GSK: Products in Development
9.3.4 GSK: Recent Developments
9.3.4.1 GSK Divestment of OTC Products
9.3.4.2 GSK Asset Swap with Novartis to Restructure Consumer Health
9.4 Johnson & Johnson
9.4.1 Johnson & Johnson: Allergic Rhinitis Drugs
9.4.2 Johnson & Johnson: Allergic Rhinitis Sales Forecast 2014-2024
9.4.3 Johnson & Johnson: Recent Developments
9.4.3.1 Launch of Zyrtec Dissolve Tabs
9.4.3.2 Manufacturing Recalls at McNeil Consumer Healthcare
9.5 Kyowa Hakko Kirin
9.5.1 Kyowa Hakko Kirin: Allergic Rhinitis Drugs
9.5.2 Kyowa Hakko Kirin: Allergic Rhinitis Sales Forecast 2014-2024
9.6 Merck & Co.
9.6.1 Merck: Allergic Rhinitis Drugs
9.6.2 Merck: Allergic Rhinitis Sales Forecast 2014-2024
9.6.3 Merck: Products in Development
9.6.4 Merck: Recent Developments
9.6.4.1 Bayer Acquires Merck’s Consumer Health Business
9.6.4.2 FDA Rejects Singulair OTC Switch
9.7 Sanofi
9.7.1 Sanofi: Allergic Rhinitis Drugs
9.7.2 Sanofi: Allergic Rhinitis Sales Forecast 2014-2024
9.8 Stallergenes
9.8.1 Stallergenes: Allergic Rhinitis Drugs
9.8.2 Stallergenes: Allergic Rhinitis Sales Forecast 2014-2024
9.8.3 Stallergenes: Products in Development
9.8.4 Stallergenes: Recent Developments
9.8.4.1 Stallergenes Acquires Argentinean Company Alergo Pharma
9.8.4.2 Greer launches Oralair in the US
9.9 UCB
9.9.1 UCB: Allergic Rhinitis Drugs
9.9.2 UCB: Allergic Rhinitis Sales Forecast 2014-2024
9.10 Other Leading Companies

10. Allergic Rhinitis Drugs Pipeline Analysis 2014-2024

10.1 Trends and Developments in the Allergic Rhinitis Pipeline
10.2 The Oral Antihistamine Pipeline
10.2.1 Talion (bepotastine, Mitsubishi Tanabe)
10.2.2 ZPL-3893787 (histamine H4R antagonist, Ziarco Pharma)
10.2.3 ZPL-868087 (oral histamine H3R antagonist, Ziarco Pharma)
10.3 The Intranasal Corticosteroids Pipeline
10.3.1 APC-3000 (HFA inhaled corticosteroid, Adamis Pharmaceuticals)
10.3.2 S0597 (topical glucocorticoid, Sun Pharma)
10.3.3 TBS-6 (Trimel Pharmaceuticals)
10.4 The Immunotherapy Pipeline
10.4.1 Actair (house dust mite SLIT, Stallergenes/Shionogi)
10.4.2 AllerT (subcutaneous birch pollen immunotherapy, Anergis)
10.4.3 Cat-SPIRE and other -SPIRE Therapies (synthetic peptide immunoregulatory epitopes, Circassia)
10.4.4 Depigoid Birch 5000 (birch pollen allergen extract, Leti Pharma)
10.4.5 House Dust Mite SLIT-Tablet (MK-8237, ALK-Abelló/Merck/Torii)
10.4.6 Pollinex Quattro (subcutaneous immunotherapies, Allergy Therapeutics)
10.4.7 gp-ASIT+ (grass pollen allergen fragments, Biotech Tools)
10.4.8 Betula verrucosa (Bet v) 1 allergen (Stallergenes)
10.5 The Pipeline for Other Allergic Rhinitis Drugs
10.5.1 eN-Lac (Lactobacillus paracasei GMNL-32, GenMont Biotech)
10.5.2 S-555739 (prostaglandin D2 receptor antagonist, Shionogi)
10.5.3 DSP-3025/AZD-8848 (toll-like receptor 7 agonist, Dainippon Sumitomo/AstraZeneca)
10.5.4 GSK2245035 (toll-like receptor 7 agonist, GSK)
10.5.5 HP-3060 (transdermal long-acting tape, Hisamitsu)
10.5.6 MRX-4 (anti-inflammatory agent, Celsus Therapeutics)
10.5.7 OC459 (Oxagen/Atopix Therapeutics/Eleventa)
10.5.8 ONO-4053 (prostaglandin D2 receptor antagonist, Ono Pharmaceutical)
10.5.9 WF10 (tetrachlorodecaoxygen chlorite matrix, Nuvo Research)
10.5.10 RPL554 (PDE-3/PDE-4 antagonist, Verona Pharma)
10.5.11 VTX-1463 (toll-like receptor 8 agonist, VentiRx)

11. Qualitative Analysis of the Allergic Rhinitis Drugs Market 2014-2024

11.1 SWOT Analysis of the Allergic Rhinitis Drugs Market
11.2 Strengths
11.2.1 High Unmet Clinical Need
11.2.2 Established Role of Allergic Rhinitis Drugs in Treatment
11.2.3 High Profile Disease Encouraging Improving Healthcare Provision
11.2.4 Increasing Consumer Demand
11.3 Weaknesses
11.3.1 Increasing Generic Penetration
11.3.2 Patient Dissatisfaction with Intranasal Corticosteroids
11.3.3 Limited Allergic Rhinitis Drugs Pipeline
11.4 Opportunities
11.4.1 The Rise of Immunotherapy
11.4.2 Higher Growth in Emerging Markets
11.4.3 Combination Drug Products
11.4.4 Rx-to-OTC Switching
11.5 Threats
11.5.1 Patent Expiry
11.5.2 Cost-Containment
11.5.3 Rising API and Manufacturing Costs
11.6 Porter’s Five Forces Analysis of the Allergic Rhinitis Drugs Market
11.6.1 Rivalry Among Competitors [High]
11.6.2 Threat of New Entrants [Low]
11.6.3 Power of Suppliers [Low]
11.6.4 Power of Buyers [Medium]
11.6.5 Threat of Substitutes [Low]

12. Research Interviews

12.1 Interview with Maureen Jenkins, Director of Clinical Services for Allergy UK, Sidcup, Kent, UK
12.1.1 Allergic Rhinitis in the UK
12.1.2 Allergic Rhinitis Treatments
12.1.3 Opportunities for Manufacturers
12.2 Interview with Kimihiro Okubo, Chairman and Professor, Department of Otolaryngology, Nippon Medical School, Tokyo, Japan
12.2.1 Allergic Rhinitis in Japan
12.3 Interview with Jonathan Bernstein, Chairman and Professor, Department of Internal Medicine, University of Cincinnati, Ohio, US
12.3.1 Allergic Rhinitis in the US
12.3.2 Nasacort AQ and OTC Nasal Sprays
12.3.3 Dymista and Combination Therapies
12.3.4 Trends and Developments in Allergic Rhinitis
12.4 Interview with Tonya Winders, President and CEO, Allergy & Asthma Network Mothers of Asthmatics, Virginia, US
12.4.1 Allergic Rhinitis in the US
12.4.2 Allergic Rhinitis Treatments
12.4.3 US Healthcare Reform and Intranasal Drugs
12.5 Interview with Allergy Medical UK, Weybridge, UK
12.5.1 Allergic Rhinitis Treatments

13. Conclusions

13.1 Allergic Rhinitis Drugs: A Mature Market
13.2 The World Allergic Rhinitis Market in 2013
13.2.1 Current Leading Allergic Rhinitis Segments
13.2.2 Leading Allergic Rhinitis Products
13.2.3 Leading Allergic Rhinitis Drugs Companies
13.2.4 Leading National Markets
13.3 World Allergic Rhinitis Drugs Market Forecast 2014-2024
13.4 Allergic Rhinitis Late-Stage Pipeline
13.5 The Future of the Allergic Rhinitis Drugs Market?

List of Tables

Table 1.1 Leading National Allergic Rhinitis Drugs Market Forecast 2014 ($m, AGR%)
Table 2.1 Leading Antihistamines for Allergic Rhinitis, 2014
Table 2.2 Leading Corticosteroids for Allergic Rhinitis, 2014
Table 2.3 Clinical Trial Phases
Table 2.4 Currency Exchange Rates, 2013
Table 3.1 Top 10 Allergic Rhinitis Drugs: Revenue ($m), 2013
Table 3.2 Top 10 Allergic Rhinitis Drug Manufacturers: Allergic Rhinitis Drugs Revenue ($m), Market Share (%), 2013
Table 3.3 World Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 3.4 Market Shares (%) of Leading Allergic Rhinitis Drugs Market Segments, 2013, 2018 and 2024
Table 4.1 World Allergic Rhinitis Drugs Market Forecast: Revenues ($m) and Market Shares (%) by National Market, 2013
Table 4.2 World Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by National Market, 2013-2024
Table 4.3 Market Shares (%) of Leading National Allergic Rhinitis Drugs Markets, 2013, 2018 and 2024
Table 4.4 US Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.5 Chinese Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.6 Japanese Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.7 EU5 Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by National Market, 2013-2024
Table 4.8 German Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.9 French Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.10 UK Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.11 Italian Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.12 Spanish Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.13 Russian Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.14 Indian Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.15 Brazilian Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.16 Mexican Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 5.1 Leading Oral Antihistamines: Revenues ($m) and Market Shares (%), 2013
Table 5.2 Oral Antihistamines Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 5.3 Oral Antihistamines Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 5.4 Sanofi: Allegra/Allegra-D/Allegra OTC Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.5 Johnson & Johnson/UCB/GSK: Zyrtec/Zyrtec-D Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.6 Merck: Claritin/Claritin OTC Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.7 Sanofi/UCB/GSK: Xyzal Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.8 Kyowa Hakko Kirin: Allelock Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.9 Merck: Clarinex Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.10 Mitsubishi Tanabe: Talion Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.11 Almirall/Dainippon Sumitomo/Takeda: Ebastel Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.1 Leading Intranasal Corticosteroids: Revenues ($m) and Market Shares (%), 2013
Table 6.2 Intranasal Corticosteroids Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 6.3 Intranasal Corticosteroids Market Forecast by Volume: Sprays (million), AGR (%), CAGR (%) by Drug, 2013-2024
Table 6.4 Intranasal Corticosteroids Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 6.5 Merck: Nasonex Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.6 Merck: Nasonex Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.7 GSK: Avamys/Veramyst Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.8 GSK: Avamys/Veramyst Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.9 GSK: Flixonase/Flonase Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.10 GSK: Flixonase/Flonase Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.11 AstraZeneca: Rhinocort Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.12 AstraZeneca: Rhinocort Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.13 Dainippon Sumitomo/Takeda: Omnaris Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.14 Dainippon Sumitomo/Takeda: Omnaris Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.15 GSK/Omega Pharma: Beconase/Beconase AQ Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.16 GSK/Omega Pharma: Beconase/Beconase AQ Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.17 Sanofi: Nasacort Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.18 Sanofi: Nasacort Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.19 Teva: QNasl Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.20 Teva: QNasl Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.21 Dainippon Sumitomo: Zetonna Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.22 Dainippon Sumitomo: Zetonna Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.23 Generic Intranasal Beclometasone Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.24 Generic Intranasal Beclometasone Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.25 Generic Intranasal Budesonide Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.26 Generic Intranasal Budesonide Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.27 Generic Intranasal Flunisolide Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.28 Generic Intranasal Flunisolide Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.29 Generic Intranasal Fluticasone Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.30 Generic Intranasal Fluticasone Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.31 Generic Intranasal Mometasone Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.32 Generic Intranasal Mometasone Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.33 Generic Intranasal Triamcinolone Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.34 Generic Intranasal Triamcinolone Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 7.1 Intranasal Antihistamines Market Forecast by Value: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 7.2 Intranasal Antihistamines Market Forecast by Volume: Sprays (million), AGR (%), CAGR (%) by Drug, 2013-2024
Table 7.3 Intranasal Antihistamines Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 7.4 Meda: Astepro Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.5 Novartis: Patanase Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.6 Meda: Astelin Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.7 Meda: Dymista Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.8 Generic Intranasal Azelastine Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.9 Generic Intranasal Azelastine Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 7.10 Generic Intranasal Olopatadine Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.11 Generic Intranasal Olopatadine Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 8.1 Leading Immunotherapy Products: Revenues ($m) and Market Shares (%), 2013
Table 8.2 Immunotherapy Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Product, 2013-2024
Table 8.3 Immunotherapy Market: Market Shares (%) by Product, 2013, 2018 and 2024
Table 8.4 Leading Immunotherapy Companies: Immunotherapy Revenue ($m) and Market Share (%), 2013
Table 8.5 Stallergenes: Staloral Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.6 ALK-Abelló: Alutard SQ Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.7 ALK-Abelló/Merck: Grazax/Grastek Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.8 Stallergenes/Greer: Oralair Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.9 Merck: Ragwitek Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.1 ALK-Abelló: Overview, 2014
Table 9.2 ALK-Abelló: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.3 GSK: Overview, 2014
Table 9.4 GSK: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.5 Johnson & Johnson: Overview, 2014
Table 9.6 Johnson & Johnson: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.7 Kyowa Hakko Kirin: Overview, 2014
Table 9.8 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.9 Merck & Co.: Overview, 2014
Table 9.10 Merck: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.11 Sanofi: Overview, 2014
Table 9.12 Sanofi: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.13 Stallergenes: Overview, 2014
Table 9.14 Stallergenes: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.15 UCB: Overview, 2014
Table 9.16 UCB: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 10.1 Allergic Rhinitis: Oral Antihistamines Pipeline, 2014
Table 10.2 Allergic Rhinitis: Intranasal Corticosteroids Pipeline, 2014
Table 10.3 Allergic Rhinitis: Immunotherapy Pipeline, 2014
Table 10.4 Allergic Rhinitis: Other Drugs Pipeline, 2014
Table 11.1 SWOT Analysis of the Allergic Rhinitis Drugs Market, 2014-2024
Table 13.1 Allergic Rhinitis Drugs Late-Stage Pipeline, 2014

List of Figures

Figure 1.1 Immunotherapy Market: Market Share (%) by Immunotherapy Type, 2013
Figure 1.2 Global Allergic Rhinitis Market Segmentation Overview, 2014
Figure 2.1 Role of Mast Cells and IgE in Allergic Rhinitis, 2014
Figure 3.1 Top 10 Allergic Rhinitis Drugs: Market Share (%), 2013
Figure 3.2 Top 10 Allergic Rhinitis Drug Manufacturers: Market Share (%), 2013
Figure 3.3 World Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 3.4 World Allergic Rhinitis Drugs Market: Market Shares (%) by Segment, 2013
Figure 3.5 World Allergic Rhinitis Drugs Market: Market Shares (%) by Segment, 2018
Figure 3.6 World Allergic Rhinitis Drugs Market: Market Shares (%) by Segment, 2024
Figure 3.7 World Allergic Rhinitis Drugs Market: Drivers and Restraints, 2014-2024
Figure 4.1 World Allergic Rhinitis Drugs Market: Revenues ($m) by National Market, 2013
Figure 4.2 World Allergic Rhinitis Drugs Market: Market Shares (%) by National Market, 2013
Figure 4.3 World Allergic Rhinitis Drugs Market: Market Shares (%) by National Market, 2018
Figure 4.4 World Allergic Rhinitis Drugs Market: Market Shares (%) by National Market, 2024
Figure 4.5 US Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.6 Chinese Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.7 Japanese Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.8 EU5 Allergic Rhinitis Drugs Market: Revenues ($m) by National Market, 2013-2024
Figure 4.9 German Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.10 French Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.11 UK Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.12 Italian Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.13 Spanish Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.14 Russian Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.15 Indian Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.16 Brazilian Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.17 Mexican Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 5.1 Oral Antihistamines Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 5.2 Oral Antihistamines Market: Market Shares (%) by Drug, 2013
Figure 5.3 Oral Antihistamines Market: Market Shares (%) by Drug, 2018
Figure 5.4 Oral Antihistamines Market: Market Shares (%) by Drug, 2024
Figure 5.5 Sanofi: Allegra Revenue ($m), AGR (%), CAGR (%), 1995-2013
Figure 5.6 Sanofi: Allegra/Allegra-D/Allegra OTC Revenue ($m), AGR (%), 2013-2024
Figure 5.7 Johnson & Johnson/UCB/GSK: Zyrtec/Zyrtec-D Revenue ($m), AGR (%), 2013-2024
Figure 5.8 Merck: Claritin/Claritin OTC Revenue ($m), AGR (%), 2013-2024
Figure 5.9 Sanofi/UCB/GSK: Xyzal Revenue ($m), AGR (%), 2013-2024
Figure 5.10 Kyowa Hakko Kirin: Allelock Revenue ($m), AGR (%), 2013-2024
Figure 5.11 Merck: Clarinex Revenue ($m), AGR (%), 2013-2024
Figure 5.12 Mitsubishi Tanabe: Talion Revenue ($m), AGR (%), 2013-2024
Figure 5.13 Almirall/Dainippon Sumitomo/Takeda: Ebastel Revenue ($m), AGR (%), 2013-2024
Figure 6.1 Intranasal Corticosteroids Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.2 Intranasal Corticosteroids Market Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.3 Intranasal Corticosteroids Market: Market Shares (%) by Drug, 2013
Figure 6.4 Intranasal Corticosteroids Market: Market Shares (%) by Drug, 2018
Figure 6.5 Intranasal Corticosteroids Market: Market Shares (%) by Drug, 2024
Figure 6.6 Merck: Nasonex Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.7 Merck: Nasonex Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.8 GSK: Avamys/Veramyst Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.9 GSK: Avamys/Veramyst Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.10 GSK: Flixonase/Flonase Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.11 GSK Flixonase/Flonase Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.12 AstraZeneca: Rhinocort Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.13 AstraZeneca: Rhinocort Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.14 Dainippon Sumitomo/Takeda: Omnaris Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.15 Dainippon Sumitomo/Takeda: Omnaris Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.16 GSK/Omega Pharma: Beconase/Beconase AQ Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.17 GSK/Omega Pharma: Beconase/Beconase AQ Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.18 Sanofi: Nasacort Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.19 Sanofi: Nasacort Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.20 Teva: QNasl Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.21 Teva: QNasl Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.22 Dainippon Sumitomo: Zetonna Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.23 Dainippon Sumitomo: Zetonna Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.24 Generic Intranasal Beclometasone Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.25 Generic Intranasal Beclometasone Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.26 Generic Intranasal Budesonide Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.27 Generic Intranasal Budesonide Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.28 Generic Intranasal Flunisolide Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.29 Generic Intranasal Flunisolide Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.30 Generic Intranasal Fluticasone Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.31 Generic Intranasal Fluticasone Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.32 Generic Intranasal Mometasone Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.33 Generic Intranasal Mometasone Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 6.34 Generic Intranasal Triamcinolone Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 6.35 Generic Intranasal Triamcinolone Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 7.1 Intranasal Antihistamines Market Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 7.2 Intranasal Antihistamines Market Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 7.3 Intranasal Antihistamines Market: Market Shares (%) by Drug, 2013
Figure 7.4 Intranasal Antihistamines Market: Market Shares (%) by Drug, 2018
Figure 7.5 Intranasal Antihistamines Market: Market Shares (%) by Drug, 2024
Figure 7.6 Meda: Astepro Revenue ($m), AGR (%), 2013-2024
Figure 7.7 Novartis: Patanase Revenue ($m), AGR (%), 2013-2024
Figure 7.8 Meda: Astelin Revenue ($m), AGR (%), 2013-2024
Figure 7.9 Meda: Dymista Revenue ($m), AGR (%), 2013-2024
Figure 7.10 Generic Intranasal Azelastine Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 7.11 Generic Intranasal Azelastine Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 7.12 Generic Intranasal Olopatadine Sales Forecast by Value: Revenue ($m), AGR (%), 2013-2024
Figure 7.13 Generic Intranasal Olopatadine Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024
Figure 8.1 Immunotherapy Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 8.2 Immunotherapy Market: Market Shares (%) by Product, 2013
Figure 8.3 Immunotherapy Market: Market Shares (%) by Product, 2018
Figure 8.4 Immunotherapy Market: Market Shares (%) by Product, 2024
Figure 8.5 Immunotherapy Market: Market Shares (%) by Leading Company, 2013
Figure 8.6 Immunotherapy Market: Market Share (%) by Immunotherapy Type, 2013
Figure 8.7 Stallergenes: Staloral Revenue ($m), AGR (%), 2013-2024
Figure 8.8 ALK-Abelló: Alutard SQ Revenue ($m), AGR (%), 2013-2024
Figure 8.9 ALK-Abelló/Merck: Grazax/Grastek Revenue ($m), AGR (%), 2013-2024
Figure 8.10 Stallergenes/Greer: Oralair Revenue ($m), AGR (%), 2013-2024
Figure 8.11 Merck: Ragwitek Revenue ($m), AGR (%), 2013-2024
Figure 9.1 ALK-Abelló: Allergic Rhinitis Drugs Revenue ($m), AGR (%), 2013-2024
Figure 9.2 GSK: Allergic Rhinitis Drugs Revenue ($m), AGR (%), 2013-2024
Figure 9.3 Johnson & Johnson: Allergic Rhinitis Drugs Revenue ($m), AGR (%), 2013-2024
Figure 9.4 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Revenue ($m), AGR (%), 2013-2024
Figure 9.5 Merck: Allergic Rhinitis Drugs Revenue ($m), AGR (%), 2013-2024
Figure 9.6 Sanofi: Allergic Rhinitis Drugs Revenue ($m), AGR (%), 2013-2024
Figure 9.7 Stallergenes: Allergic Rhinitis Drugs Revenue ($m), AGR (%), 2013-2024
Figure 9.8 UCB: Allergic Rhinitis Drugs Revenue ($m), AGR (%), 2013-2024
Figure 11.1 Porter’s Five Forces Analysis of the Allergic Rhinitis Drugs Market, 2014-2024

掲載企業リスト

Companies Listed

ActoGeniX
Adamis Pharmaceuticals
Alcon (subsidiary of Novartis)
Alembic
Alergo Pharma (acquired by Stallergenes)
ALK-Abelló
Allergologisk Laboratorium København (ALK) (now ALK-Abelló)
Allergology Laboratory (now ALK-Abelló)
Allergopharma (acquired by Merck Group)
Allergy Medical UK
Allergy Therapeutics
Allermed Laboratories (acquired by Greer)
Almirall
Altana Pharma (acquired by Nycomed)
Ampio
Anergis
Antigen Laboratories (acquired by Greer)
Apotex
Archimedes Pharma (acquired by Kyowa Hakko Kirin)
Ares Life Sciences
Aspen Pharmacare
AstraZeneca
Atopix Therapeutics
Aventis (merged into Sanofi)
Barr Laboratories (subsidiary of Teva)
Bausch + Lomb (acquired by Valeant)
Bayer
Belcher Pharmaceuticals
Bio-Medical Services (acquired by ALK-Abelló)
Biopol Laboratory (acquired by ALK-Abelló)
Biotech Tools
Biotechnology Value Fund
BMP Sunstone (part of Sanofi)
Boehringer Ingelheim
Caremark CVS
Catalent Pharma Solutions
Celltech (part of UCB)
Celsus Therapeutics
Center Laboratories (acquired by ALK-Abelló)
Chattem (part of Sanofi)
Cipla
Circassia Pharmaceuticals
Daewon
Dainippon Sumitomo
DBV Technologies
Dongkook
Dr. Reddy's Laboratories
Eddingpharm
Eleventa LLC
Entod
Express Scripts
Fountain Biopharma
GenMont Biotech
Genzyme (part of Sanofi)
Glycomar
Glycores
Greer Laboratories (acquired by Ares Life Sciences)
Grifols
GSK (GlaxoSmithKline)
HAL Allergy
Hanlim
Hi Tech Pharma
Hisamitsu Pharmaceutical Co.
Hoechst AG
Human Genome Sciences (acquired by GSK)
Inspire Pharmaceuticals (acquired by Merck)
Institut Mérieux
Intas Pharmaceuticals
Janssen Pharmaceutica (subsidiary of Johnson & Johnson)
Johnson & Johnson (J&J)
Jubilant HollisterStier
Kalypsys
Keldman Healthcare
Kyowa Hakko Kirin
Laboratorios Leti
Leti Pharma (subsidiary of Laboratorios Leti)
Lupin
McNeil Consumer Healthcare (subsidiary of Johnson & Johnson)
Meda
Medley (acquired by Sanofi)
MedPointe Inc.
Merck & Co. (Merck)
Merck Group (Merck-Serono; Merck KGaA)
Merck Sharp & Dohme (MSD) (subsidiary of Merck)
Mitsubishi Tanabe
Mylan
Nektar Therapeutics
Nelco Laboratories (acquired by ALK-Abelló)
Nippon Paper Group
Novartis
Nuvo Research
Nycomed (subsidiary of Takeda)
Omega Pharma
Ono Pharmaceutical
Oxagen Limited
Perrigo
Pfizer
Prestige Brands
Prostrakan (subsidiary of Kyowa Hakko Kirin)
Reckitt Benckiser
Roxane Laboratories (subsidiary of Boehringer Ingelheim)
Sam Chun Dang
Sam-A
Sandoz (generics division of Novartis)
Sanofi
Sanofi Pasteur (part of Sanofi)
Schering-Plough (merged into Merck)
Schwarz Pharma (part of UCB)
Sepracor (now Sunovion Pharmaceuticals)
Shionogi
Stallergenes
Stiefel Laboratories (part of GSK)
Sun Pharma
Sunovion Pharmaceuticals (subsidiary of Dainippon Sumitomo)
Synthélabo (merged into Sanofi)
Synthes Inc. (acquired by Johnson & Johnson)
Takeda
Teva
Torii
Trimel Pharmaceuticals
Ube Industries
UCB
VentiRx
Verona Pharma
Vespa Laboratories (acquired by ALK-Abelló)
ViiV Healthcare (GSK-Pfizer joint venture)
WellPoint Healthcare
Wockhardt
Zeltia
Zentiva (acquired by Sanofi)
Ziarco Pharma

Other Organisations Mentioned in this Report

Allergy & Asthma Network Mothers of Asthmatics (AANMA)
Allergy UK
American Academy of Allergy, Asthma and Immunology (AAAAI)
Bank of Spain
China Food and Drug Administration (CFDA)
Consumer Healthcare Products Association (CHPA) (US)
Department of Pharmaceuticals (India)
European Medicines Agency (EMA)
Haute Autorité de Santé (France)
Health and Social Care Information Centre (UK)
Health Canada
Imperial College London
Japanese Society of Allergology
Ministry of Agriculture, Forestry and Fisheries (Japan)
Ministry of Food and Drug Safety (MFDS) (South Korea)
Ministry of Health, Labour and Welfare (MHLW) (Japan)
National Health Service (NHS) (UK)
National Pharmaceutical Pricing Authority (India)
Nippon Medical School
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pollen UK
Rashtriya Swasthya Bima Yojana (India)
Servicio Sanitario Nazionale (SSN) (Italy)
Unified Health System (SUS) (Brazil)
United States Food and Drug Administration (FDA)
Université Libre de Bruxelles
University of Cincinnati
University of Leuven
US Securities and Exchange Commission (SEC)
World Allergy Organization (WAO)
World Health Organization (WHO)

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。